Skip to main content
CDC Website

Technical Assistance

Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)

Human immunodeficiency virus (HIV) infection is widely prevalent in individuals in the reproductive age group. Globally, an estimated 1.3 million people living with HIV (PWH) become pregnant each year (UNAIDS data, 2019). With the advent of antiretroviral therapy (ART), significant progress has been made in the prevention of vertical transmission of HIV. However, although ART has clear benefits in preventing vertical transmission, ART regimens are associated with higher rates of preterm birth, stillbirth, and early infant death.

Comprehensive Alcohol-HIV/AIDS Research Center (P60 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) seeks applications for research center grants to conduct high-impact research on alcohol and HIV/AIDS. Through this NOFOA, NIAAA seeks to encourage research applications aimed to address the impact of alcohol use (and related other substance use, mental health, and pharmacological/medication complications) on the most important challenges for controlling and ending HIV/AIDS pandemic.

Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)

This initiative will support multilevel and multidisciplinary intervention research to improve quality of life and promote successful aging among people with HIV with HIV associated non-AIDS comorbidities across the life course from racial and ethnic and lower socioeconomic status groups.

Locally Led Development Annual Program Statement (APS)

The goal of this APS is to partner with numerous stakeholders to contribute to achieving the USAID/Guatemala’s Country Development Cooperation Strategy (CDCS) 2020-2025 goal. This goal is to advance Guatemala’s development by connecting indigenous peoples, women, and youth to opportunities that enable them to achieve prosperous, secure, and dignified lives at home in Guatemala. 

Engaging Survivors of Sexual Violence and Trafficking in HIV and Substance Use Disorder Services (R34 Clinical Trial Optional)

The goal of this concept is to support exploratory research and preliminary interventions to address the interrelated and compounding contextual factors that contribute to substance use and HIV risk among sexual trafficking survivors.

UNIVERSAL HEALTH CARE PROJECT APS

The U.S. Agency for International Development (USAID) Mission in the Philippines is pleased to announce the Universal Health Care Project (UHCP) Annual Program Statement (APS), which will improve health outcomes of underserved and vulnerable Filipinos in alignment with the United States Government (USG), USAID, and Philippine government objectives to achieve Universal Health Care (UHC). The UHCP is a suite of awards built to strategically improve national and local health systems in the Philippines across an integrated health portfolio.

Notice of Special Interest (NOSI): Advancing Biomedical Research in Pulmonary Non-Tuberculosis Mycobacterial (NTM) Infections

This NOSI aims to stimulate advances in diagnosis and treatment of NTM infections that cause or exacerbate pulmonary disease such as Mycobacterium abscessus, Mycobacterium avium complex, and Mycobacterium kansasii.  Areas of interest include but are not limited to:

HIV Prevention and Alcohol (R34 Clinical Trials Optional)

The FOA seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research.

The US HIV Prevention and Alcohol (R01 Clinical Trials Optional)

The FOA seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research.